U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249840) titled 'Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis' on Oct. 16.
Brief Summary: The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are:
* Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon?
* Is ropeginterferon safe to use in these patients?
Participants will:
* Receive ropeginterferon as an injection under the skin onc...